Significant resurgence from Big Pharma in the top 10 Innovation Index

29 March 2018

The eighth annual Pharmaceutical Innovation Index, released by IDEA Pharma, throws up a few surprises.

The Pharmaceutical Innovation Index (PII) measures, scores and celebrates a company's ability to deliver innovation to patients, by objectively evaluating performance based on a rolling five year period (2012-2017), and operates on the simple premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?

The biggest shaker this year is AstraZeneca (LSE: AZN), coming from the middle of the pack in 2017 to take the 2018 PII crown. Gilead Sciences (Nasdaq: GILD) also continued its PII ascent, to second place, advancing from 2017's 3rd. Johnson & Johnson (NYSE: JNJ), having ceded the top spot last year after a four-year run on top, was able to regain some of the lost ground in 2018, landing in a joint 3rd spot with a rapidly-improving Novartis (NOVN: VX). At the other end of the scale, Takeda Pharmaceutical (TYO: 4502) dropped from 5th place to 31st.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK